Chang P, Attili CD, Calderón PG, López R

Language: Spanish
References: 20
Page: 30-35
PDF size: 267.52 Kb.

ABSTRACT

According to the World Health Organization (WHO), leishmaniasis is one of the seven most important tropical diseases that represents a global health problem and yet one of the most neglected diseases. Approximately 350 million people are at risk of contracting the disease and it is estimated that 1.6 million new cases occur worldwide each year. We present the case of a 32-year-old male patient who was referred with a 3-month old lesion on lips, which started as a “small ball” in the lower lip and progressively extended, increasing in size and ulcerating until the whole upper lip was covered. At the time of evaluation, he presented with stomatitis located in the lips (upper and lower) constituted by edema, ulcers, crusts and yellowish discharge. The patient had recently traveled to Peten, Guatemala, which is an endemic area of leishmaniasis. Lower lip biopsies were performed and sent to the Central Unit for PCR-DNA analysis at the National Health Laboratory. The PCR-DNA test confirmed the diagnosis of leishmaniasis due to Leishmania sp. and treatment was started with glucantime at a dose of 20 mg/kg/day for 20 days intramuscularly, obtaining an excellent clinical response. Leishmaniasis lesions occur in areas of the body exposed to the bite of sand flies (Plhebotomus and Lutzomyia). The most involved areas of the body are the ears, cheeks, nose, and extremities. Labial leishmaniasis as the primary site of cutaneous leishmaniasis is unusual and can mimic other pathologies such as oral granulomatosis in Crohn’s disease, sarcoidosis, giant cell granuloma, squamous cell carcinoma, fungal infections among others. Although labial lesions are an unusual presentation of leshmaniasis, it’s important to consider it under the differential when patients have travelled to endemic areas so that early diagnosis and timely treatment can be started.

REFERENCES

1. Marra F, Chiappetta M y Vincenti V, Ear, nose and throat manifestations of mucocutaneous leishmaniasis: a literature review, Acta Biomed 2014; 85(1): 3-7.

2. Georgiadou S, Makaritsis K y Dalekos G, Leishmaniasis revisited: current aspects on epidemiology, diagnosis and treatment, Journal of Translational Internal Medicine 2015; 3(2).

3. World Health Organization, Leishmaniasis fact sheet. Disponible en: http://www.who.int/news-room/fact-sheets/detail/leishmaniasis. Consultado: 14 de marzo de 2018.

4. Torres-Guerrero E, Quintanilla-Cedillo MR, Ruiz-Esmenjaud J y Arenas R, Leishmaniasis: a review, F1000Research 2017, 6(F1000 Faculty Rev):750.

5. Mohammadpour I, Motazedian M, Handjani F y Hatam F, Lip leishmaniasis: a case series with molecular identification and literature review, bmc Infectious Diseases 2017; 17:96:2178-7.

6. Hammami-Ghorbel H, Abda B, Badri T, Chelbi H, Fenniche S, Mokhtar I, Bouratbine A, Benmously-Mlika R y Aoun K, Mucosal leishmaniasis of the lip: an emerging clinical form in Tunisia, Journal of European Academy of Dermatology and Venereology 2014; doi: 10.1111/jdv.12580.

7. Vasudevan B y Bahal A, Leishmaniasis od the lip diagnosed by lymph node aspiration and treated with a combination of oral ketoconazole and intralesional sodium stibogluconate, Indian Journal of Dermatology 2011; 56(2):214-6.

8. Ayatollahi J, Ayatollahi F, Ayatollahi R y Hossein S, A case-study of mucosal leishmaniasis in the lip, Int J Infect 2017; 4(3):e38932.

9. Chávez Vásquez E, Leishmaniasis Guatemala 2016, Departamento de Epidemiología, Ministerio de Salud Pública y Asistencia Social, Guatemala. Disponible en: http://epidemiologia.mspas.gob.gt//.

10. Centro de Estudios de la Salud, Universidad del Valle de Guatemala, Hoja Informativa, Leishmaniasis. Disponible en: http://www.ces.uvg. edu.gt/page/leishmaniasis/.

11. Sajad P, Rather S, Hassan I y Qureshi W, Primary lip leishmaniasis-report of 4 cases from a non-endemic region of Kashmir valley of north India and review of literature, Journal of Advances in Medicine and Medical Research 2017; 24(1):1-5.

12. Nasiri S, Mozafari N y Abdollahimajd F, Unusual presentation of cutaneous leishmaniasis: lower lip ulcer, Archives of Clinical Infectious Diseases 2012; 7(2):66-8.

13. Faber W, Oskam L, Van Gool T, Kroon N, Knegt-Junk K, Hofwegen H, Van der Wal A y Kager P, Value of diagnostic techniques for cutaneous leishmaniasis, J Am Acad Dermatol 2003; 49:70-4.

14. Espir T, Guerreiro T, Naiff M, Figueira LP, Soares FV, Silva S y Ramos AM, Evaluation of different diagnostic methods of American cutaneous leishmaniasis in the Brazilian Amazon, Experimental Parasitology 2016; 167:1-6.

15. Akhoundi M, Downing T, Votýpka J, Kuhls K, Lukes J, Cannet A, Ravel C, Marty P, Delaunay P, Kasbari M, Granouillac B, Gradoni L y Sereno D, Leishmania infections: molecular targets and diagnosis, Molecular Aspects of Medicine 2017; 57:1e29.

16. Antonio LF, Fagundes A, Oliveira RV, Pinto PG, Bedoya-Pacheco SJ, Vasconcellos EC, Valete-Rosalino MC, Lyra MR, Passos SR, Pimentel MI y Schubach AO, Montenegro skin test and age of skin lesion as predictors of treatment failure in cutaneous leishmaniasis, Rev Inst Med Trop Sao Paulo 2014; 56(5):375-80.

17. Pourmohammadi B, Motazedia MH, Hata GR, Kalantari M, Habibi P y Sarkari B, Comparison of three methods for diagnosis of cutaneous leishmaniasis, Iranian J Parasitol 2010; 5(4):1-8.

18. Sundar S y Chakravarty J, An update on pharmacotherapy for leishmaniasis, Expert Opin Pharmacother 2015; 16(2):237-52.

19. Machado PR, Ampuero J, Guimarães LH, Villasboas L, Rocha AT et al., Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial, plos Negl Trop Dis 2010; 4(12):e912.

20. Lanza E, Rabello A y Fernandes F, Efiicacy of azole therapy for tegumentary leishmaniasis: a systematic review and meta-analysis, plos One 2017; 12(10):E0186117.